Ensysce Biosciences Conference Participation Announcement
Analysis based on 6 articles · First reported Sep 02, 2026 · Last updated Sep 02, 2026
The announcement is routine and unlikely to materially affect Ensysce's stock price. It signals ongoing investor engagement and potential regulatory developments in psychedelic therapeutics, but no immediate financial impact is expected.
Forte Biosciences, a clinical-stage biotechnology company, announced its participation in several upcoming investor conferences and industry events in September 2026. These include the Cantor Global Healthcare Conference, the H.C. Wainwright 28th Annual Global Investment Conference, an FDA public hearing on psychedelic drug therapeutics, the Life Sciences Product Launch Summit, and the 20th Annual Pain Therapeutics Summit. The company will present at the Cantor conference and will hold one-on-one meetings with investors. Ensysce is developing neuroplastogenic therapies for chronic pain and novel opioids with reduced abuse potential.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard